The U.S. Food and Drug Administration on Friday approved an oral version of Novo Nordisk's diabetes drug semaglutide, a boost for the Danish drugmaker, which hopes to transform the market by offering patients a noninjectable treatment.
from RSSMix.com Mix ID 8870618 https://yhoo.it/30iZxRK
Be First to Post Comment !
Post a Comment
Note: Only a member of this blog may post a comment.